Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS:GTSIF) CEO Philip Young presents at Proactive's One2One virtual investor forum.
The Vancouver-based company is currently advancing unique medicines and devices to treat mild traumatic brain injury and post-traumatic stress disorder, as well as other indications. With five provisional patents, a pre-clinical study underway and a drug delivery device in engineering development, Lobe is quickly making a name for itself in the world of psychedelics.
Price: 0.175 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lobe Sciences Ltd named herein, including the promotion by the Company of Lobe Sciences Ltd in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE
We are delighted to invite you to attend the next Proactive ONE2ONE Investor Forum which is taking place on Tuesday February 23rd from 1pm EST via our online interactive webinar conference Proactive continues to bring you the best investment opportunities safely to the comfort of your own...
Industry & services
Mining
